The drug tPA (tissue-type plasminogen activator) can break up the blood clots that cause strokes and heart attacks, but it can also loosen the blood-brain barrier and generate inflammation in the brain. In mice, genetically removing LRP1, a receptor for tPA, from brain cells called microglia can soften tPA’s harmful effects. Blocking LRP1 could make tPA safer.